International Reports Synergistic
Enhancement of Ozone Therapy Efficacy in Prostate, Breast and
Ovarian Cancer Cells by Pterostilbene
Clinical Stage Cancer
Immunotherapy Biotechnology Company Files Patent Expanding Uses of
its Pterostilbene Based Product Pipeline
Oceanside, CA -- August 13,
2018 -- InvestorsHub NewsWire -- Therapeutics Solutions
International, Inc., (OTC
Markets: TSOI) announced today filing of a
patent on recent data showing pterostilbene potently augments
killing of breast cancer, prostate cancer, and ovarian cancer cells
by ozone therapy.
The data are an extension
of ongoing work at the Company seeking to identify means of
enhancing the effects of pterostilbene administration for treatment
of a variety of cancers, as well as enhancing the efficacy of
existing cancer therapies.
Previously the Company has
been granted United States Patent # 9,682,047 covering augmentation
of immunotherapy efficacy using pterostilbene administration.
Furthermore, the Company has developed NanoStilbene, a
nanotechnology-based product that enhances optimal delivery of
pterostilbene to tissue. In the current patent application,
administration of ozone in conjunction with various concentrations
of pterostilbene resulted in enhanced tumor cell killing, without
killing of control, non-cancer cells.
"The ability of ozone gas
to possess a selective ability to kill cancer cells compared to
non-cancer cells has been known since the 1980 publication by Sweet
et al in the prestigious peer-reviewed journal Science1.
Furthermore, peer-reviewed studies have demonstrated that ozone
therapy can enhance cancer-killing effects of chemotherapy2" said
Timothy Dixon, President, and CEO of Therapeutic Solutions
International. "By demonstrating potentiation of the cancer-killing
effects of ozone therapy by pterostilbene, we anticipate initiating
collaborations with international doctors studying the efficacy of
this modality in the treatment of cancer."
International has performed clinical pharmacokinetic studies using
NanoStilbene to deliver pterostilbene. The concentrations of
pterostilbene that are found in the blood 4 hours after oral
administration of NanoStilbene are sufficient to enhance the
cancer-killing effect of ozone therapy based on data presented in
the patent application.
"Pterostilbene is known to
kill cancer cells in part through increasing endoplasmic reticulum
stress selectively in tumors and not in healthy cells3. Our
hypothesis was that ozone therapy may alter endoplasmic
reticulum-associated molecular pathways, and thus a synergistic
effect may be observed" said Dr. James Veltmeyer, Chief Medical
Officer of the Company. "By understanding molecular mechanisms of
"alternative medicines" such as ozone therapy, we can identify ways
of leveraging their effects and developing therapeutic approaches
that have higher chances of success."
internationally are using ozone therapy and other means of
oxidative medicine to treat chronic illness. Although techniques
such as autohemotherapy have a very strong safety record, little
work is being conducted at elucidating mechanisms of action and
identifying ways of integrating these approaches into conventional
cancer care" said Dr. Juergen Winkler, Member of the Company's
Scientific Advisory Board and Medical Director of Quantum
Functional Medicine. "The medical doctors and scientists at
Therapeutic Solutions International are leading the way in
developing scientific understanding for molecular mechanisms of
alternative medical immunotherapies in an objective and rigorous
manner. By combining alternative medicine with cutting edge
science, I am eager to watch the proper clinical trial translation
that TSOI has performed in taking these concepts from bench to
Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation
for the treatment of several specific diseases. Immune modulation
refers to the ability to upregulate (make more active) or
downregulate (make less active) one's immune system. The Company's
corporate website is www.therapeuticsolutionsint.com.
1 Sweet et al. Ozone
selectively inhibits growth of human cancer cells. Science. 1980
Aug 22;209(4459):931-3. https://www.ncbi.nlm.nih.gov/pubmed/7403859
2 Zanker et al. In vitro
synergistic activity of 5-fluorouracil with low-dose ozone against
a chemoresistant tumor cell line and fresh human tumor cells.
Chemotherapy. 1990;36(2):147-54. https://www.ncbi.nlm.nih.gov/pubmed/2311442
3 Papandreou et al. Plant
stilbenes induce endoplasmic reticulum stress and their anti-cancer
activity can be enhanced by inhibitors of autophagy. Exp Cell Res.
2015 Nov 15;339(1):147-53. https://www.ncbi.nlm.nih.gov/pubmed/26477823
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements